Nalu Medical Secures $65 Million Investment to Advance Their Neurostimulation Device

Located in the US, Nalu Medical has secured $65 million in a late-stage investment phase to accelerate the research and production of their neurostimulation device targeting long-term pain management.  

The financial support will predominantly expedite the commercial expansion and broaden the clinical research for the Nalu device that incorporates the micro-implantable pulse generator. 

Novo Holdings spearheaded the funding, with active involvement from Aperture Venture Partners, Gilde Healthcare, MVM Partners, and Pura Vida, among other big investors. 

The business concentrates on offering a non-surgical and non-opioid therapeutic alternative for patients experiencing persistent neuropathic pain. 

Tom West, the leading executive at Nalu Medical, commented, “The Nalu team is excited about meaningfully expanding and improving the treatment options in the peripheral nerve pain space by setting a new standard of care.” 

West went on to add, “We continue to invest in building clinical data to expand access for patients who often don’t have other therapeutic options.” 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.